Heidi O. Flemmen

Skien, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.

Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.

Journal: The New England journal of medicine

Published: July 01, 2026

Between-hospital variation in discontinuation of treatment with dimethyl fumarate in multiple sclerosis.

Between-hospital variation in discontinuation of treatment with dimethyl fumarate in multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: May 12, 2026

Differences in Income Growth Between People With Multiple Sclerosis and Controls: A Norwegian Cohort Study.

Differences in Income Growth Between People With Multiple Sclerosis and Controls: A Norwegian Cohort Study.

Journal: European journal of neurology

Published: December 19, 2025

Brain MRI findings in patients with post COVID-19 condition: frequency and longitudinal changes in a nationwide cohort study.

Brain MRI findings in patients with post COVID-19 condition: frequency and longitudinal changes in a nationwide cohort study.

Journal: Frontiers in neurology

Published: July 08, 2025

Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study.

Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 17, 2025

Amyotrophic lateral sclerosis caused by the C9orf72 expansion in Norway - prevalence, ancestry, clinical characteristics and sociodemographic status.

Amyotrophic lateral sclerosis caused by the C9orf72 expansion in Norway - prevalence, ancestry, clinical characteristics and sociodemographic status.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: September 24, 2024

Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence study.

Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence study.

Journal: Multiple sclerosis and related disorders

Published: July 23, 2024

The influence of menopause on multiple sclerosis.

The influence of menopause on multiple sclerosis.

Journal: European journal of neurology

Published: March 07, 2024

Repeat expansions in AR, ATXN1, ATXN2 and HTT in Norwegian patients diagnosed with amyotrophic lateral sclerosis.

Repeat expansions in AR, ATXN1, ATXN2 and HTT in Norwegian patients diagnosed with amyotrophic lateral sclerosis.

Journal: Brain communications

Published: September 21, 2023

"No association between disease modifying treatment and fatigue in multiple sclerosis".

"No association between disease modifying treatment and fatigue in multiple sclerosis".

Journal: Multiple sclerosis and related disorders

Published: March 06, 2023

Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population.

Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population.

Journal: Frontiers in neurology

Published: September 01, 2022

Six versus 2 weeks treatment with doxycycline in European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blinded, randomised and placebo-controlled trial.

Six versus 2 weeks treatment with doxycycline in European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blinded, randomised and placebo-controlled trial.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: June 01, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026